• Clinicians should consider using these drugs only if neither baricitinib nor IL-6 receptor blockers (tocilizumab or sarilumab) are available.
• The GDG emphasized the need for more trial evidence to better inform the recommendations

Practical info Route, dosage and duration: We refer to the table of trial characteristics (ruxolitinib and tofacitinib) to guide the administration of these agents, in the absence of other available information. Timing: Ruxolitinib or tofacitinib (like IL-6 receptor blockers) should be initiated with systemic corticosteroids; specific timing during hospitalization or the course of illness is not specified.